This Week in Cardiology: 07/17/15

The past few weeks have been filled with exciting news for the cardiology community. Here are some of the top stories we've collected from around the Web: 

67% of Adults Should Do This to Avoid Heart Attacks 

According to a new study published in the Journal of the American Medical Association (AMA), the pool of candidates that can be treated with statins can be expanded to 67% of all U.S. adults between the ages of 40-75. It is projected that this could prevent an additional 161,560 cardiovascular events, including heart attack, stroke, and others. 

The Lowdown on TAVR: As Risk Drops, Expectations Rise 

Cardiovascular Business reports on the five-year results from the PARTNER I trial (Placement of Aortic Transcatheter Valves Trial), which show that 5 years after implant, "valves showed no signs of deterioration with durable hemodynamics." With risk down, GlobalData now projects that the compound annual growth rate for TAVR valves will increase 19.7% between 2013 and 2020. 

New "Once-in-a-Decade" Novartis Drug for Heart Failure Approved by FDA 

The Food and Drug Administration (FDA) has approved a new heart failure drug by Novartis, which has been met with considerable support from the medical community. The drug - Entresto - is the first in a new class of drugs called angiotensin receptor neprilysin inhibitors that is used to treat high blood pressure and congestive heart failure while enhancing neurohormonal systems. 

Comments

Comments are closed on this post.
  • RSS

Statistics

  • Entries (235)
  • Comments (1069)

Categories